141 related articles for article (PubMed ID: 30617140)
1. Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer.
Lee JB; Kang H; Fang L; D'Souza C; Adeyi O; Zhang L
Clin Cancer Res; 2019 Apr; 25(7):2241-2253. PubMed ID: 30617140
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
3. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15.
Yao J; Ly D; Dervovic D; Fang L; Lee JB; Kang H; Wang YH; Pham NA; Pan H; Tsao MS; Zhang L
J Immunother Cancer; 2019 Jan; 7(1):17. PubMed ID: 30670085
[TBL] [Abstract][Full Text] [Related]
4. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.
Fang KK; Lee J; Khatri I; Na Y; Zhang L
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
[TBL] [Abstract][Full Text] [Related]
6. Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy.
Chen B; Lee JB; Kang H; Minden MD; Zhang L
J Exp Clin Cancer Res; 2018 Apr; 37(1):88. PubMed ID: 29690909
[TBL] [Abstract][Full Text] [Related]
7. DNT Cell-based Immunotherapy: Progress and Applications.
Li Y; Dong K; Fan X; Xie J; Wang M; Fu S; Li Q
J Cancer; 2020; 11(13):3717-3724. PubMed ID: 32328176
[TBL] [Abstract][Full Text] [Related]
8. The abnormal lpr double-negative T cell fails to proliferate in vivo.
Sobel ES; Kakkanaiah VN; Rapoport RG; Eisenberg RA; Cohen PL
Clin Immunol Immunopathol; 1995 Feb; 74(2):177-84. PubMed ID: 7828372
[TBL] [Abstract][Full Text] [Related]
9. Double-negative T cells: a promising avenue of adoptive cell therapy in transplant oncology.
Hu Z; Yang M; Chen H; He C; Lin Z; Yang X; Li H; Shen W; Lu D; Xu X
J Zhejiang Univ Sci B; 2023 May; 24(5):387-396. PubMed ID: 37190888
[TBL] [Abstract][Full Text] [Related]
10. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
11. NK cells specifically TCR-dressed to kill cancer cells.
Mensali N; Dillard P; Hebeisen M; Lorenz S; Theodossiou T; Myhre MR; Fåne A; Gaudernack G; Kvalheim G; Myklebust JH; Inderberg EM; Wälchli S
EBioMedicine; 2019 Feb; 40():106-117. PubMed ID: 30665853
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
13. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
[TBL] [Abstract][Full Text] [Related]
14. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
Bailey CP; Budak-Alpdogan T; Sauter CT; Panis MM; Buyukgoz C; Jeng EK; Wong HC; Flomenberg N; Alpdogan O
Oncotarget; 2017 Jul; 8(27):44366-44378. PubMed ID: 28574833
[TBL] [Abstract][Full Text] [Related]
15. A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.
Golay J; D'Amico A; Borleri G; Bonzi M; Valgardsdottir R; Alzani R; Cribioli S; Albanese C; Pesenti E; Finazzi MC; Quaresmini G; Nagorsen D; Introna M; Rambaldi A
J Immunol; 2014 Nov; 193(9):4739-47. PubMed ID: 25267972
[TBL] [Abstract][Full Text] [Related]
16. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.
Schmid H; Schneidawind C; Jahnke S; Kettemann F; Secker KA; Duerr-Stoerzer S; Keppeler H; Kanz L; Savage PB; Schneidawind D
Front Immunol; 2018; 9():1817. PubMed ID: 30127790
[TBL] [Abstract][Full Text] [Related]
17. High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.
Mossoba ME; Halverson DC; Kurlander R; Schuver BB; Carpenter A; Hansen B; Steinberg SM; Ali SA; Tageja N; Hakim FT; Gea-Banacloche J; Sportes C; Hardy NM; Hickstein DD; Pavletic SZ; Khuu H; Sabatini M; Stroncek D; Levine BL; June CH; Mariotti J; Rixe O; Fojo AT; Bishop MR; Gress RE; Fowler DH
Clin Cancer Res; 2015 Oct; 21(19):4312-20. PubMed ID: 26071480
[TBL] [Abstract][Full Text] [Related]
18. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
19. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy.
Meehan KR; Wu J; Webber SM; Barber A; Szczepiorkowski ZM; Sentman C
Cytotherapy; 2008; 10(1):30-7. PubMed ID: 18202972
[TBL] [Abstract][Full Text] [Related]
20. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
